

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On December 5, 2005

TOWNSEND and TOWNSEND and CREW LLP

By:

Jo Ann Honcik Dallara



PATENT
Attorney Docket No.: 15280W-002100US
Client Ref. No.: E-286-1998/1-US-06
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRENNEMAN *et al.*

Application No.: 10/049,587

Filed: February 12, 2002

For: ORALLY ACTIVE PEPTIDES
THAT PREVENT CELL DAMAGE AND
DEATH

Confirmation No. 9701

Examiner: Standley, Steven H.

Art Unit: 1649

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed November 4, 2005, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification as follows.

Appl. No. 10/049,587

Amdt. dated December 5, 2005

Reply to Office Communication of November 4, 2005

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 10 of this paper.